{
  "case_id": "MN21-36487",
  "year": 2021,
  "patient_info": {
    "age_range": "31 to 40",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Biologics",
  "treatments_requested": [
    {
      "name": "Rituximab",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_but_failed": [
    {
      "name": "Azathioprine",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Mycophenolate Mofetil",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity"
  ],
  "other_issues": null,
  "guidelines_support": true,
  "guidelines_not_support": null,
  "guidelines_details": "The American College of Rheumatology guidelines support the use of Rituxan for lupus nephritis when standard treatments fail.",
  "soc_support": true,
  "soc_not_support": null,
  "soc_details": "Rituxan is indicated for treatment when standard therapies like Imuran and Cellcept fail.",
  "study_support": null,
  "study_details": [],
  "key_questions": [
    "medical_necessity"
  ],
  "expedited": false,
  "rationale": "The requested medication, Rituxan, is medically necessary due to the patient's poor response to standard therapies for SLE, as supported by guidelines from the American College of Rheumatology.",
  "reviewer_credentials": "Board certified in internal medicine with sub-specialty certification in rheumatology, actively practicing with expertise in treating similar conditions."
}